| Literature DB >> 25091658 |
Jean-Baptiste Guy1, Jane-Chloé Trone1, François Casteillo2, Fabien Forest2, Cécile Pacaut3, Coralie Moncharmont1, Sophie Espenel1, Alexis Vallard1, Julien Langrand Escure1, Olivier Collard3, Michel Peoc'h2, Nicolas Magné1.
Abstract
Carcinosarcoma, also known as mixed mesodermal tumor or malignant mixed Mullerian tumor (MMMT) is a pathological entity combining a sarcomatous and a carcinomatous component. Found in thoracic, digestive, genitourinary, liver or skin locations, the most common location is the female genital tract. In gynecological tumors, carcinosarcoma accounts for about 2-5% of endometrial cancers, and 1% of ovarian cancers. To date, there is no consensus on the therapeutic strategy. It relies mostly on maximum cytoreductive surgery. Adjuvant therapy remains controversial, and few prospective studies investigating its interest. Retrospective studies show the benefits of adjuvant chemotherapy based on platinum in most cases. Radiation therapy has a place in the adjuvant situations of endometrial and cervical carcinosarcoma. A more detailed pathological knowledge, and the use of targeted therapies may be promising in this histological subtype whose prognosis remains very poor. The objective of this study is to present the main principles of carcinosarcoma management in female genital tracts, describing pathological and prognostic features at the same time.Entities:
Keywords: carcinosarcoma; cervix; endometrial; female genital tract; malignant mixed mullerian tumor; ovary; vagina
Mesh:
Year: 2014 PMID: 25091658 DOI: 10.1684/bdc.2014.1937
Source DB: PubMed Journal: Bull Cancer ISSN: 0007-4551 Impact factor: 1.276